Comparison of IO-IO and IO-TKI Treatment Outcomes in Metastatic Renal Cell Carcinoma: Influence of Metastatic Site Count
The number of metastatic organs affects the efficacy of IO-TKI but has no effect on the efficacy of IO-IO treatment. We recommend considering the number of metastatic organs as an additional prognostic factor to optimize treatment selection for patients with mRCC.
Authors
- T. Habuchi
- Yuki Takai (ORCID: https://orcid.org/0000-0001-6506-5313)
- Hiroshi Kikuchi (ORCID: https://orcid.org/0000-0003-0067-4606)
- Yoichi M. Ito (ORCID: https://orcid.org/0000-0001-5073-0827)
- Kazuyuki Numakura (ORCID: https://orcid.org/0000-0002-5899-1738)
- N. Tsuchiya
- Ryuji Matsumoto (ORCID: https://orcid.org/0000-0001-9363-9054)
- Yuya Sekine
- Takashige Abe (ORCID: https://orcid.org/0000-0002-5468-7632)
- Nobuo Shinohara
- Ojiro Tokairin
- Sei Naito
- Haruka Miyata
- Takahiro Osawa
Institutions
- Yamagata University (JP)
- Akita University (JP)
- Hokkaido University (JP)
- Hokkaido University Hospital (JP)
Publication Details
- Journal
- Cancer Diagnosis & Prognosis
- Published
- 2026-01-03
- DOI
- https://doi.org/10.21873/cdp.10513
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00